SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark Pharmaceuticals presents Phase 2a data on GBR 830

18 May 2018 Evaluate

Glenmark Pharmaceuticals has presented new data from a Phase 2a, proof-of-concept study of GBR 830, an investigational, anti-OX40 monoclonal antibody being studied for the treatment of moderate-to-severe atopic dermatitis (AD), that were presented at the International Investigative Dermatology Meeting (IID) in Orlando, Florida. The exploratory Phase 2a study was conducted to investigate the safety of GBR 830, evaluate its effects on AD biomarkers, and generate the first clinical evidence of its biological activity.

Patients were randomized to receive two doses of GBR 830 or placebo, and were assessed for response at Day 29 and Day 71. New data from the study demonstrated that subsequent to treatment with GBR 830, epidermal hyperplasia, proliferation, and mRNA biomarkers for disease activity were reduced, indicating a possible effect on both the acute and chronic stages of AD.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

2371.05 -2.70 (-0.11%)
07-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1834.40
Dr. Reddys Lab 1306.80
Cipla 1362.85
Zydus Lifesciences 940.10
Lupin 2459.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×